Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Current Liabilities (2019 - 2026)

Biodesix filings provide 8 years of Total Current Liabilities readings, the most recent being $14.5 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 8.81% to $14.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.5 million, a 8.81% increase, with the full-year FY2025 number at $17.4 million, up 21.79% from a year prior.
  • Total Current Liabilities hit $14.5 million in Q1 2026 for Biodesix, down from $17.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $37.4 million in Q3 2022 to a low of $13.0 million in Q3 2024.
  • Median Total Current Liabilities over the past 5 years was $22.1 million (2023), compared with a mean of $23.2 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 84.89% in 2022 and later crashed 60.3% in 2024.
  • Biodesix's Total Current Liabilities stood at $22.8 million in 2022, then surged by 46.31% to $33.4 million in 2023, then crashed by 57.16% to $14.3 million in 2024, then rose by 21.79% to $17.4 million in 2025, then decreased by 16.9% to $14.5 million in 2026.
  • The last three reported values for Total Current Liabilities were $14.5 million (Q1 2026), $17.4 million (Q4 2025), and $18.2 million (Q3 2025) per Business Quant data.